Hormone combo tested for clues to appetite and energy control

NCT ID NCT05681299

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing how growth hormone and liraglutide (a diabetes drug) affect appetite, energy use, and blood sugar in healthy adults and those with growth hormone deficiency. Forty participants will receive each treatment or placebo for 21 days, with blood tests and body measurements taken. The goal is to understand how these hormones work together, not to treat a disease directly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
growth hormone and liraglutide
What this could lead to
If successful, this could help explain how these hormones regulate appetite and metabolism, potentially guiding future treatments for obesity or hormone deficiencies.
What could go wrong
This is a small, early-phase study (40 participants) focused on biological markers, not clinical outcomes. Results may not translate to real-world benefits or apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GROWTH HORMONE DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Neuroendocrine Unit and Pituitary Center, Columbia University Irving Medical Center

    RECRUITING

    New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.